$162.00
The 50mg research format of OVA’s NNMT inhibitor — for women running extended protocols or stacking with GLP-1 peptides and NAD+ for compounding metabolic effects.
3-5 business days
SSL encrypted
5-Amino-1MQ inhibits NNMT — the enzyme that hijacks NAD+ precursors in adipose tissue and locks fat cells in storage mode. At the 50mg vial size, this format is optimized for extended use or for women who have confirmed their response at the 5mg level and are ready for a full 12-week protocol. NNMT inhibition has demonstrated effects beyond fat loss in research contexts, including improved insulin signalling, reduced inflammatory cytokine production from adipose tissue, and protection against diet-induced metabolic dysfunction.
The 50mg vial also makes 5-Amino-1MQ practical as a long-term metabolic support compound — it can be run alongside GLP-1 peptides like tirzepatide during active protocols, or continued as a maintenance compound after completing a GLP-1 cycle to prevent metabolic regression. For perimenopausal women in whom rising NNMT activity compounds estrogen-related metabolic changes, this dual intervention approach addresses the problem from two directions.
Female-calibrated dosing: 1–2mg injectable daily or 5 days/week. The 50mg vial supports a full 8–12 week protocol at standard doses. Do not exceed 2mg daily without clinical guidance. Cycle 8–12 weeks on, 4 weeks off.
Storage: Store lyophilized powder below -20°C. After reconstitution, refrigerate at 2–8°C and use within 30 days.
| Dosage | 50mg |
|---|---|
| Format | Injectable Vial |
| Cycle Length | 8–12 weeks |
| Storage | Freeze until use. Refrigerate after reconstitution. Use within 30 days. |
Reviews
There are no reviews yet.